Nexipox Vaccine 0.5ml Vaccine

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Nexipox Vaccine 0.5ml Vaccine can also have adverse effects on the body, most of which resolve without the need for medical attention.

Some common side effects include:

• Injection site reactions (pain, swelling, redness)
  
• Headache
  
• Irritation
  
• Drowsiness
  
• Loss of appetite

Seek medical attention in case of any unusual or severe side effects immediately.

Nexipox Vaccine 0.5ml Vaccine should be given by an experienced nurse or doctor. Please do not self-administer.It is given to children between 12 months to 12 years of age.

Also the second dose should be given after a minimum gap of 3 months. For adolescents & adults as well, it is given in two doses a minimum of 4 weeks apart.

• Nexipox Vaccine 0.5ml Vaccine contains Varicella Vaccine (live) attenuated (2000PFU) as an active ingredient.
• This vaccine helps to develop immunity by initiating a mild infection also this type of infection does not cause illness.
• Mild infection caused by vaccine stimulate the body's immune system to produce antibodies to protect against any future infections.
• It can be given from children between 12 months to 12 years of age and to adolescents and adults as well. Vaccination is the best way to prevent chickenpox.
  

• Liu, H., Cui, L., Zhang, S., Wang, H., Xue, W., Li, H., ... & Li, S. (2025). Research Progress on Varicella-Zoster Virus Vaccines. Vaccines, 13(7), 730.
  
• Grose, C., Friedrichs, W. E., & Smith, K. O. (1981). Cryopreservation of varicella-zoster virions without loss of structural integrity or infectivity. Intervirology, 15(3), 154-160.
  
• AboulFotouh, K., Xu, H., Moon, C., Williams III, R. O., & Cui, Z. (2022). Development of (inhalable) dry powder formulations of AS01B-containing vaccines using thin-film freeze-drying. International Journal of Pharmaceutics, 622, 121825.
  
• Hansen, L. J. J., Daoussi, R., Vervaet, C., Remon, J. P., & De Beer, T. R. M. (2015). Freeze-drying of live virus vaccines: A review. Vaccine, 33(42), 5507-5519.
  
• Wui, S. R., Kim, K. S., Ryu, J. I., Ko, A., Do, H. T. T., Lee, Y. J., ... & Lee, N. G. (2019). Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice. Vaccine, 37(15), 2131-2141.
  
• Garg, P., Garg, S. P., Sharma, M. K., & Sahani, S. (2014). Phase-I, open, unicentric clinical trial for evaluation of safety of varicella vaccine, live (IP)(Oka strain) in adults. Biotechnology International, 7, 26-34.​